Medication used to treat a viral infection
POPULARITY
18 episodes with antivirals
10 episodes with antivirals
3 episodes with antivirals
3 episodes with antivirals
3 episodes with antivirals
2 episodes with antivirals
2 episodes with antivirals
2 episodes with antivirals
2 episodes with antivirals
In this episode, Martin Witzenrath, MD, FERS, and Michele Bartoletti, MD, PhD, discuss the management of mild to moderate COVID-19 in patients who are immunocompromised, including:Initial workup, which may include laboratory tests and/or imagingLatest data on the use of remdesivir or nirmatrelvir plus ritonavir for mild to moderate COVID-19, including considerations for drug–drug interactions Presenters:Martin Witzenrath, MD, FERSMedical DirectorCharite Centrum 12Internal Medicine & DermatologyProfessor and Chair for Respiratory Medicine and Critical CareDepartment of Infectious Disease, Respiratory Medicine and Critical CareCharite Campus Mitte/Campus Virchow Klinikum/Campus Benjamin FranklinCharite – University of BerlinBerlin, GermanyMichele Bartoletti, MD, PhDAssociate Professor of Infectious DiseasesDepartment of Biomedical SciencesHumanitas UniversityPieve Emanuele (MI), ItalyHead of Infectious Diseases UnitIRCCS Humanitas Research HospitalRozzano (MI), Italy Link to full program: https://bit.ly/4gu2gcUDownloadable slides: https://bit.ly/3CGlDBSGet access to all of our new podcasts by subscribing to the CCO Infectious Disease Podcast on Apple Podcasts, Google Podcasts, or Spotify.
A new year brings new questions and more insights to the topic of Highly Pathogenic Avian Influenza. Dr. Mike Brasher is joined by leading experts in the field of avian influenza, Dr. Dave Stallknecht, Dr. Richard Webby, and Dr. Jennifer Ballard to discuss the current status of avian influenza, what we've learned since 2022, and what we still don't understand. Recent changes have been noted in the genetic code of the circulating virus, but what does this mean for the risk it poses to birds, mammals, and humans? How do we study these changes? What waterfowl species are most affected, and do we understand why these effects differ among species? Also discussed is recent science about risks to hunting dogs, what hunters need to do if they observe sick or dead birds, why hunters should be vigilant about being tested for avian flu if they feel ill, and how we can all work to reduce the likelihood of the virus becoming more severe. Tune in for an information-packed episode that is of growing relevance to everyone.Listen now: www.ducks.org/DUPodcastSend feedback: DUPodcast@ducks.org
Are you up to date on who is at risk for severe COVID-19 outcomes? Learn from our experts in this quickfire question-and-answer activity. Credit available for this activity expires: 1/3/2026 Earn Credit / Learning Objectives & Disclosures: https://www.medscape.org/viewarticle/1002037?ecd=bdc_podcast_libsyn_mscpedu
In this episode, we review the high-yield topic Antivirals from the Drugs section at Medbullets.com Follow Medbullets on social media: Facebook: www.facebook.com/medbullets Instagram: www.instagram.com/medbulletsofficial Twitter: www.twitter.com/medbullets Linkedin: https://www.linkedin.com/company/medbullets
Long Covid Action Project (LCAP) activists Corsi Rosenthal (CR) and Clean Air (CA), along with journalist and LCAP founder Joshua Pribanic, discuss the recent direct action CR and CA participated in to disrupt the National Institute of Health's (NIH) first meeting for the RECOVER Initiative, ostensibly created to "understand, treat, and prevent Long COVID" in the United States. / Episode notes: https://www.lastborninthewilderness.com/episodes/lcap-activists-2 // Sustain + support: https://www.patreon.com/lastborninthewilderness // Donate: https://www.paypal.me/lastbornpodcast
Long Covid Action Project (LCAP) activists Corsi Rosenthal (CR) and Clean Air (CA), along with journalist and LCAP founder Joshua Pribanic, discuss the recent direct action CR and CA participated in to disrupt the National Institute of Health's (NIH) first meeting for the RECOVER Initiative, ostensibly created to "understand, treat, and prevent Long COVID" in the United States. // Support the work and listen to the full interview: https://www.patreon.com/lastborninthewilderness
Go To: https://www.moneytreepublishing.com/shop USE code: BAAL for 10% OFF your entire order.Want to be Awesome, and never be censored? Make a Login account at: https://FTJMedia.com and find my channel at https://FTJMedia.com/channel/BaalBustersTired of Ads? I have no control over what ads this distributor selects. I do not endorse or share their sentiment. GET COMMERCIAL FREE VIDEOS/PODCASTS and Exclusive Content: Become a Patron. https://Patreon.com/DisguisetheLimitsWe Live in conquered and claimed territory. We are being systematically culled in many ways, but none more active and prevalent than what we mistake as our Health Care. This system of medicine was installed, not because it was the best for you, but because it was the most efficient method of killing. With no one the wiser, these murderers, the Eugenicists could practice in the open using the most vicious and horrific indiscrimination. This was brought to you by men in fraternities, men who did the work of the Lurian Kabbalists, and their later termed "Zionist" agenda, fueled by the money power of the world, the Rothschild Counterfeiting syndicate.JOIN this Site!DR PETER GLIDDEN, ND Health Recovery Site:https://leavebigpharmabehind.com/?via=pgndhealthUse Code baalbusters for 50% OFF - LIMITED TIME Just For UsFor the 90 Essential Nutrients, Contact Brenda here: 888 618 1796 ext. 101 Mention the Show!YOU ARE the CHANGE. You ARE the Sponsors.Support the Show Here: https://GiveSendGo.com/BaalBustersEuropean Viewers You can support here: https://www.tipeeestream.com/baalbusters/GET COMMERCIAL FREE VIDEOS/PODCASTS and Exclusive Content: Become a Patron. https://Patreon.com/DisguisetheLimitsMy Clean Source Creatine-HCL https://www.semperfryllc.com/store/p126/CreatineHCL.htmlGo to https://SemperFryLLC.com to get all the AWESOME stuff I make plus use code Victory for 11% OFF just for BB viewers!Quick Links to Dr Monzo and Dr Glidden are found on my website.Want to send me something?Baal Busters Broadcast#1029101 W 16th Street STE AYuma, AZ 85364BE ADVISED: If you are compelled to mail a check for show support, it must be written out to Semper Fry, LLC.Thanks!Become a supporter of this podcast: https://www.spreaker.com/podcast/ba-al-busters-broadcast--5100262/support.
Steven E. Phillips, MD is a Yale-trained, expert on zoonotic infections and coauthor of the book CHRONIC. He specializes in treating medicine's most complex cases, which include Lyme & other vector-borne disease and long COVID. Additionally, he has served as an expert for the states of CT, NY, RI, and VT, providing testimony during their respective public hearings, which resulted in changes to existing healthcare laws. Dr. Phillips has been a longstanding public face of the Lyme pandemic. He is currently spearheading a drug development effort to bring public a durable, effective treatment for some of these infections, which will hopefully change how we treat a range of rheumatologic and neurologic illnesses. Dr. Phillips also sits on the Bay Area Lyme Foundation's scientific advisory board.
Free book is here at https://www.memorizingpharm.com/books Summary 3.14 Antivirals Nursing Pharmacology Chapter 3.14 discusses antivirals, a medication class used to treat viral infections. It covers subclasses like antiherpes (e.g., acyclovir), antiinfluenza (e.g., oseltamivir), anti-hepatitis, and antiretrovirals (e.g., HIV treatment). These drugs inhibit viral replication at different stages, requiring timely administration. Important considerations include monitoring renal function, medication compliance, and potential side effects like fatigue. Multiple Choice Questions Which is a common use for acyclovir? a) Bacterial infections b) Genital herpes c) Fungal infections d) Hypertension How does oseltamivir work? a) Prevents protein synthesis b) Blocks virus release c) Inhibits cell wall synthesis d) Enhances DNA replication Which virus is treated with antiretrovirals? a) Influenza b) HIV c) Hepatitis d) Herpes What is a critical monitoring aspect for patients on antivirals? a) Blood pressure b) Renal function c) Heart rate d) Blood sugar When should oseltamivir be administered for best results? a) After 5 days of symptoms b) Within 48 hours of symptom onset c) Only if fever is present d) Anytime during the illness Answer Key b) Genital herpes b) Blocks virus release b) HIV b) Renal function b) Within 48 hours of symptom onset
My special guest is Christopher Vasey who's here to discuss his book called Natural Antibiotics and Antivirals: 18 Infection-Fighting Herbs and Essential Oils Explains how to use medicinal herbs and essential oils to fight infectious illness, strengthen the immune system, and combat antibiotic resistance • Presents 18 of the most potent antibiotic and antiviral herbs and one beehive remedy, propolis, detailing how to use them and what illnesses each is best suited to treat • Reveals how natural antibiotics have antiviral properties, lack side effects, and have no adverse effects on non-targeted bacteria, such as intestinal flora • Also includes info on restoring gut health with probiotics, strengthening your immune system to become less receptive to infections, and supporting natural antibiotics with detox treatments Nature offers us many natural antibiotics from the plant kingdom that work powerfully against germs while also being gentle on the body. Knowledge of these safe and natural antibiotics and antivirals is more crucial now than ever as modern antibiotics become less and less effective due to the growing threat of antibiotic-resistant germs. Natural antibiotics even offer an opportunity to reverse antibiotic resistance by reducing the use of pharmaceutical antibiotics to only the most critical cases. In this practical guide, Christopher Vasey presents 18 of the most potent antibiotic and antiviral herbs from around the world and one beehive remedy, propolis. He details how to use them effectively as mother tinctures and essential oils as well as what illnesses each is best suited to treat. Drawing on the latest research, he explains how microbes can't build resistance against these natural substances due to the many molecules in their make-up and their large spectrum of action in the body, which makes them effective against viruses as well. He reveals that, unlike pharmaceutical antibiotics and antivirals whose list of side effects grows in proportion to their strength, natural antibiotics generally lack any malignant side effects and have no adverse effects on non-targeted bacteria, such as intestinal flora. The author also includes information on probiotics to restore gut health after the use of pharmaceutical antibiotics, ways to strengthen your immune system and become less receptive to infections, and guidance on detox treatments to support the natural antibiotics as they work. He also provides an index of more than 50 common ailments and diseases with the most effective medicinal plants and essential oils to use in each case. Offering a way to break free from the threat of antibiotic-resistant germs and improve the body's immune system and internal terrain, this guide gives each of us the ability to fight infections naturally.Follow Our Other ShowsFollow UFO WitnessesFollow Crime Watch WeeklyFollow Paranormal FearsFollow Seven: Disturbing Chronicle StoriesJoin our Patreon for ad-free listening and more bonus content.Follow us on Instagram @mysteriousradioFollow us on TikTok mysteriousradioTikTok Follow us on Twitter @mysteriousradio Follow us on Pinterest pinterest.com/mysteriousradio Like us on Facebook Facebook.com/mysteriousradio
Send us a textAntibiotics, antivirals, and antifungals have revolutionized modern medicine, saving countless lives and transforming our approach to infectious diseases. In this episode of our podcast, we delve into the differences between these powerful tools of modern medicine. We explore their discovery, impacts, and the pressing issue of evolving resistance. We dive into where we get antibiotics, how they work and why responsible antibiotic use is so important to prevent antibiotic resistance. We highlight the critical role of accurate diagnosis and appropriate treatment of bacterial infections to prevent resistance from developing. We also dive in to the intricate interactions between microorganisms and our immune system. For instance, certain fungi and bacteria are essential for maintaining a healthy balance, but under specific conditions, they can cause infections. We discuss fungal pathogens like rose gardener's disease and aspergillus, emphasizing the importance of understanding fungal infections, especially in the context of rising global temperatures and their impact on fungal behavior. Antivirals, another critical class of antimicrobials, target viral infections by preventing viruses from replicating. This episode explores the challenges in developing effective antivirals, such as the rapid mutation rates of viruses and the difficulty of targeting viral components without harming host cells. Effective antiviral treatment often requires early administration, and the episode discusses the various forms these medications can take, from pills to intravenous injections. This episode provides a comprehensive guide to the world of antimicrobials, blending historical insights and scientific knowledge. We underscore the importance of responsible antibiotic use, the challenges of treating evolving and emerging diseases, and the critical role of the human microbiome. Listeners are encouraged to rethink their interactions with these microscopic beings and appreciate the delicate balance required to maintain health in the face of evolving pathogens. Whether you're a healthcare professional, a science enthusiast, or someone interested in the history or future of medicine, this episode offers valuable insights into the complex and fascinating world of antimicrobials. Tune in to learn more about how these powerful drugs have shaped our past, present, and future in the fight against infectious diseases.Thanks for listening to the Infectious Science Podcast. Be sure to visit infectiousscience.org to join the conversation, access the show notes, and don't forget to sign up for our newsletter to receive our free materials. We hope you enjoyed this new episode of Infectious Science, and if you did, please leave us a review on Apple Podcasts and Spotify. Please share this episode with others who may be interested in this topic! Also, please don't hesitate to ask questions or tell us which topics you want us to cover in future episodes. To get in touch, drop us a line in the comment section or send us a message on social media. Twitter @Infectious_SciInstagram @InfectscipodFacebook Infectious Science PodcastSee you next time for a new episode!
Antivirals are a group of drugs that have always foxed the clinicians. With limited use on a daily basis, we tend to forget about these drugs unless faced with an imminent situation where their use becomes imperative. This podcast where Brig (Dr) J Muthukrishnan reunites with Wg Cdr (Dr) Rohit Vashisht the ID specialist from AFMC, brings forth the bare essentials about this very important group of drugs which will enable you to use them in your clinical practice better.
The effect of pantoprazole on eGFR slope, antiviral medications for Herpes Zoster, & link between pediatric AKI in Uzbekistan and cough syrups are covered in this episode of ASN Kidney Translation: An ASN Journals' Podcast.
The Real Truth About Health Free 17 Day Live Online Conference Podcast
In this episode, Mark S. Sulkowski, MD, FIDSA, FAASLD; Tatyana Kushner, MD, MSCE; Paul Y. Kwo, MD; and patient advocate Jacki Chen, PhD, consider barriers and solutions for more expansive HBV treatment in the United States. Topics include:Patient subgroups to consider for treatment outside guideline criteriaAdverse event and cost-effectiveness considerationsIntegration of patient perspectives in wider treatmentPresenters:Mark S. Sulkowski, MD, FIDSA, FAASLDProfessor of MedicineDirector, Division of Infectious Diseases, Johns Hopkins Bayview Medical CenterJohns Hopkins University School of MedicineBaltimore, MarylandTatyana Kushner, MD, MSCEAssociate ProfessorDivision of Liver DiseasesIcahn School of Medicine at Mount SinaiNew York, New YorkPaul Y. Kwo, MDProfessor of MedicineDirector of HepatologyStanford University School of MedicinePalo Alto, CaliforniaJacki Chen, PhDPatient Advocate Link to full program: https://bit.ly/3TuqFHILink to the slides:https://bit.ly/4a60GM4Get access to all of our new podcasts by subscribing to the CCO Infectious Disease Podcast on Apple Podcasts, Google Podcasts, or Spotify.
In this episode, Mark S. Sulkowski, MD, FIDSA, FAASLD; Tatyana Kushner, MD, MSCE; Paul Y. Kwo, MD; and patient advocate Jacki Chen, PhD, consider barriers and solutions for more expansive HBV treatment in the United States. Topics include:Patient subgroups to consider for treatment outside guideline criteriaAdverse event and cost-effectiveness considerationsIntegration of patient perspectives in wider treatmentPresenters:Mark S. Sulkowski, MD, FIDSA, FAASLDProfessor of MedicineDirector, Division of Infectious Diseases, Johns Hopkins Bayview Medical CenterJohns Hopkins University School of MedicineBaltimore, MarylandTatyana Kushner, MD, MSCEAssociate ProfessorDivision of Liver DiseasesIcahn School of Medicine at Mount SinaiNew York, New YorkPaul Y. Kwo, MDProfessor of MedicineDirector of HepatologyStanford University School of MedicinePalo Alto, CaliforniaJacki Chen, PhDPatient Advocate Link to full program: https://bit.ly/3TuqFHILink to the slides:https://bit.ly/4a60GM4Get access to all of our new podcasts by subscribing to the CCO Infectious Disease Podcast on Apple Podcasts, Google Podcasts, or Spotify.
In this episode, Mark S. Sulkowski, MD, FIDSA, FAASLD; Tatyana Kushner, MD, MSCE; Paul Y. Kwo, MD; and patient advocate Jacki Chen, PhD, consider barriers and solutions for more expansive HBV treatment in the United States. Topics include:Patient subgroups to consider for treatment outside guideline criteriaAdverse event and cost-effectiveness considerationsIntegration of patient perspectives in wider treatmentPresenters:Mark S. Sulkowski, MD, FIDSA, FAASLDProfessor of MedicineDirector, Division of Infectious Diseases, Johns Hopkins Bayview Medical CenterJohns Hopkins University School of MedicineBaltimore, MarylandTatyana Kushner, MD, MSCEAssociate ProfessorDivision of Liver DiseasesIcahn School of Medicine at Mount SinaiNew York, New YorkPaul Y. Kwo, MDProfessor of MedicineDirector of HepatologyStanford University School of MedicinePalo Alto, CaliforniaJacki Chen, PhDPatient Advocate Link to full program: https://bit.ly/3TuqFHILink to the slides:https://bit.ly/4a60GM4Get access to all of our new podcasts by subscribing to the CCO Infectious Disease Podcast on Apple Podcasts, Google Podcasts, or Spotify.
In this episode, Mark S. Sulkowski, MD, FIDSA, FAASLD; Tatyana Kushner, MD, MSCE; Paul Y. Kwo, MD; and patient advocate Jacki Chen, PhD, consider barriers and solutions for more expansive HBV treatment in the United States. Topics include:Patient subgroups to consider for treatment outside guideline criteriaAdverse event and cost-effectiveness considerationsIntegration of patient perspectives in wider treatmentPresenters:Mark S. Sulkowski, MD, FIDSA, FAASLDProfessor of MedicineDirector, Division of Infectious Diseases, Johns Hopkins Bayview Medical CenterJohns Hopkins University School of MedicineBaltimore, MarylandTatyana Kushner, MD, MSCEAssociate ProfessorDivision of Liver DiseasesIcahn School of Medicine at Mount SinaiNew York, New YorkPaul Y. Kwo, MDProfessor of MedicineDirector of HepatologyStanford University School of MedicinePalo Alto, CaliforniaJacki Chen, PhDPatient Advocate Link to full program: https://bit.ly/3TuqFHILink to the slides:https://bit.ly/4a60GM4Get access to all of our new podcasts by subscribing to the CCO Infectious Disease Podcast on Apple Podcasts, Google Podcasts, or Spotify.
In this episode, Renslow Sherer, MD, and Trinh P. Vu, PharmD, BCIDP, discuss how to optimize the use of COVID-19 antivirals and how to navigate drug-drug interactions between COVID-19 treatments and a patient's home medications. Their discussion includes:Current COVID-19 landscapeCOVID-19 testing and vaccination recommendationsTreatment guidelines and antiviral options for nonhospitalized adults with COVID-19Resources for assessing and managing COVID-19 antiviral-related drug-drug interactionsAnswers to learners' most pressing questionsPresenters:Renslow Sherer, MDProfessor of MedicineSection of Infectious Diseases and Global HealthUniversity of ChicagoChicago, IllinoisTrinh P. Vu, PharmD, BCIDPClinical Pharmacy Specialist in Infectious DiseasesDepartment of PharmacyEmory University Hospital MidtownAtlanta, GeorgiaSlideset: https://bit.ly/4c6kwbJDownloadable resource:https://bit.ly/49rofP6Full program: https://bit.ly/3P16TR8Get access to all of our new podcasts by subscribing to the CCO Infectious Disease Podcast on Apple Podcasts, Google Podcasts or Spotify.
ICYMI
Episode 2 - Latest Update on Urgent Virus Outbreaks, August 2023 Dialogue on Urgent Viral Diseases This episode of Going anti-Viral features an IAS–USA Dialogue titled "Latest Update on Urgent Virus Outbreaks," which is a panel discussion held on August 1, 2023. Dr Paul A. Volberding from the University of California San Francisco serves as the moderator and welcomes three distinguished panelists: Dr Carlos del Rio from Emory University, Yvonne Maldonado from Stanford University and Dr Michael Saag from the University of Alabama Birmingham. discuss recent developments in COVID-19, MPOX, RSV, and HIV. This includes the the paradigm-shifting results of the REPRIEVE study, current hurdles in COVID-19 vaccination and antiviral treatment, and trends in RSV and MPOX. They also discuss the overall impact of COVID-19 on education and child development. 00:08 Introduction and Panel Discussion Overview 01:56 Discussion on the REPRIEVE Study 05:59 COVID-19 Updates and Vaccination Challenges 13:35 The Role of Antivirals in COVID-19 Treatment 20:39 Future of COVID-19 Vaccines and Age Group Considerations 27:20 The Importance of Transparency28:18 The Need for Open Discussions on COVID-19 Vaccines 29:47 The Existential Threat to Science-Based Medicine 31:49 The Challenge of Testing for RSV 33:11 The Potential Impact of RSV Vaccines 36:45 The Ongoing Struggle with Long COVID-19 42:46 The Increasing Cases of MPOX 48:27 The Tragic Impact of the Pandemic on Education 53:42 The Importance of In-Person Interactions 54:10 Closing Remarks __________________________________________________Produced by IAS-USA, Going anti–Viral is a podcast for clinicians involved in research and care in HIV, its complications, and other viral infections. This podcast is intended as a technical source of information for specialists in this field, but anyone listening will enjoy learning more about the state of modern medicine around viral infections. Going anti-Viral's host is Dr Michael Saag, a physician, prominent HIV researcher at the University of Alabama at Birmingham, and volunteer IAS–USA board member. In most episodes, Dr Saag interviews an expert in infectious diseases or emerging pandemics about their area of specialty and current developments in the field. Other episodes are drawn from the IAS–USA vast catalogue of panel discussions, Dialogues, and other audio from various meetings and conferences.
In this episode, Hannah Imlay, MD, MS, discusses cytomegalovirus (CMV) prevention strategies in solid organ transplantation (SOT) recipients including:Strategies for preventing CMV in SOTInternational guideline recommendations for CMV prevention strategies by organ typeAntivirals used for CMV preventionComparison of preemptive therapy vs prophylaxis for CMV prevention in liver transplant recipientsComparison of letermovir vs valganciclovir for CMV prophylaxis in kidney transplant recipientsUse of CMV cell–mediated immunity monitoring for primary prophylaxisMonitoring CMV viral loads, including limitations to quantitative nucleic acid testingFuture prevention approachesFaculty:Hannah Imlay, MD, MSAssistant Professor of MedicineDepartment of Internal Medicine, Division of Infectious DiseasesUniversity of Utah Salt Lake City, UtahContent based on a CME program supported by an educational grant from Merck & Co., Inc., Rahway, NJ, USA.Follow along with a downloadable slideset at: https://bit.ly/476v2wILink to full program: https://bit.ly/47lNK2K
In this episode, Raymund Razonable, MD, discusses cytomegalovirus (CMV) management strategies beyond primary prophylaxis in solid organ transplantation recipients including:CMV treatment goals CMV treatment and monitoring recommendationsRole of secondary prophylaxisUse of CMV cell–mediated immunity (CMI) monitoring for CMV relapse riskUse of CMV CMI for secondary prophylaxis Proposed use of CMV CMI monitoring for secondary prophylaxisIncidence and outcomes with antiviral resistance Risk factors for CMV resistanceWhen to suspect antiviral resistance Testing for antiviral resistance using genotypic assaysOutcomes in patients with ganciclovir-resistant vs ganciclovir-susceptible virusTreatment recommendations for resistant/refractory CMVEfficacy and safety of maribavir vs investigator-assigned therapy for resistant/refractory CMV infections from the phase III SOLTICE studyTreatment algorithm for resistant/refractory CMV Adjunctive, investigational, and off-label treatment options for resistant/refractory CMV Faculty:Raymund Razonable, MDProfessor of MedicineProgram Director, Infectious Diseases FellowshipVice Chair, Division of Infectious DiseasesMayo ClinicRochester, Minnesota Content based on a CME program supported by an educational grant from Merck & Co., Inc., Rahway, NJ, USA.Follow along with a downloadable slideset at: https://bit.ly/476v2wILink to full program: https://bit.ly/47lNK2K
Arthur Kim, MD, and Renslow Sherer, MD, discuss how new data on COVID-19 vaccines and treatments may affect practice, including:Real-world data on COVID-19 outcomesCOVID-19 prevention: current and emerging conceptsCOVID-19 therapeutics: new clinical trial and real-world dataPresenters:Arthur Kim, MDAssociate Professor of MedicineHarvard Medical SchoolDivision of Infectious DiseasesMassachusetts General HospitalBoston, MassachusettsRenslow Sherer, MDDirectorInternational HIV Training CenterProfessor of MedicineSection of Infectious Diseases and Global HealthDepartment of MedicineUniversity of ChicagoChicago, IllinoisFollow along with the slides at:https://bit.ly/40DFjhvLink to full program: https://bit.ly/3FI8HJx
Dr. Rod Quilitz, Lead Pharmacist and Antimicrobial Stewardship Program Coordinator at Moffitt Cancer Center and Research Institute, presents a comprehensive talk on the use of antifungal agents and antivirals in the Malignancy patient. Dr Quilitz begins by reviewing the mechanisms of action of different antifungal drug classes. He next discusses Polyene antifungals, azoles, echinocandins in order and includes information on their structure, indications, spectrum of action, dosing information, and toxicities. Lastly, Dr Quilitz discusses antivirals used in the treatment of Herpesvirus family infections, including acyclovir, ganciclovir, foscarnet, cidofovir, and others.
Find out from expert Dr Saye Khoo how to manage COVID-19 drug-drug interactions (DDIs). Credit available for this activity expires: 10/20/2024 Earn Credit / Learning Objectives & Disclosures: https://www.medscape.org/viewarticle/997480?ecd=bdc_podcast_libsyn_mscpedu
It's In the News, a look at the top stories and headlines from the diabetes community happening now. Top stories this week: lots of news from the EASD conference, including info from Dexcom, Vertex, and more, the ADA issues new guidelines for CGM use at school around caregivers' ability to follow, a new study says women should be screened at a younger age for type 2 diabetes, and congrats to Lauren Dahlin, who lives with type 1, for qualifying for the Ironman race in Hawaii. Find out more about Moms' Night Out Please visit our Sponsors & Partners - they help make the show possible! Take Control with Afrezza Omnipod - Simplify Life Learn about Dexcom Edgepark Medical Supplies Check out VIVI Cap to protect your insulin from extreme temperatures Learn more about AG1 from Athletic Greens Drive research that matters through the T1D Exchange The best way to keep up with Stacey and the show is by signing up for our weekly newsletter: Sign up for our newsletter here Here's where to find us: Facebook (Group) Facebook (Page) Instagram Twitter Check out Stacey's books! Learn more about everything at our home page www.diabetes-connections.com Reach out with questions or comments: info@diabetes-connections.com Hello and welcome to Diabetes Connections In the News! I'm Stacey Simms and these are the top diabetes stories and headlines happening now XX In the news is brought to you by Edgepark simplify your diabetes journey with Edgepark XX Lots of news out of EASD – the European Association for the Study of Diabetes happening this week. Including, a new trial finds that antiviral medications, when given soon after a child is diagnosed with type 1 diabetes, might help preserve those vital beta cells. The team followed 96 children aged 6 to 15 who were all diagnosed with type 1 diabetes within three weeks prior to their enrollment in the study. The children were randomly selected to receive either the two antiviral medicines or a placebo for six months. After one year of follow-up, the researchers found that C-peptide levels remained "significantly higher" in kids who'd gotten the antiviral treatment compared to those who hadn't. That suggests the treatment helped shield the child's pancreatic beta cells from destruction. While C-peptide levels dropped a full 24% in children who received the placebo, it fell by just 11% in those who got the antivirals, the investigators found. On top of that, 86% of kids who'd gotten the antivirals still produced their own insulin at a level that makes treatment with supplementary insulin easier, the team said, and is also known to be linked to lowered risks for diabetes complications. The treatment appeared to be safe, with no severe side effects noted. According to Mynarek's team, their research supports the notion "that a low-grade persistent virus infection is an underlying disease mechanism, and that type 1 diabetes may be prevented by development of new vaccines." The researchers concluded that "further studies should be done at an earlier stage in the disease process, to evaluate whether antiviral treatment could delay the progression of beta-cell damage leading to clinical type 1 diabetes." https://consumer.healthday.com/type-1-diabetes-2665779376.html XX Also at EASD, an update on once a week insulin icodec for the treatment of type 1 diabetes. While several other studies have investigated once-weekly insulins in type 2 diabetes, this was the first data to be presented from a large-scale phase 3 study in type 1 diabetes. The study, ONWARDS 6, included 582 people with type 1 diabetes who received either insulin icodec or insulin degludec. Participants had an average age of 44 years and an average diabetes duration of 20 years. Both the icodec and degludec group received basal insulin in combination with mealtime insulin (insulin aspart, or NovoLog) over a period of 57 weeks. Overall, participants treated with once-weekly icodec and once-daily icodec had similar reductions in A1C of -0.5%, suggesting that this new insulin may offer another option for treating type 1 diabetes. What were the key findings? This study showed that insulin icodec was effective at reducing A1C in people with type 1 diabetes, although icodec did lead to higher rates of hypoglycemia compared to degludec. Researchers are still investigating some questions related to the hypoglycemia events that occurred in this trial, such as how the time of injection and exercise may affect hypoglycemia. https://diatribe.org/once-weekly-insulins-type-1-diabetes-latest-research-update XX XX Vertex Pharmaceuticals says a third type 1 patient no longer needs insulin after it's investigational stem cell-derived therapy VX-880, being assessed for type 1 diabetes. Two patients who had been followed for at least 12 months likewise met the study's endpoint of the elimination of serious hypoglycemic events (SHE) between 90 days and 12 months. Tuesday's results follow an earlier data drop in June 2023, detailing the first two patients that achieved insulin independence and met the study's primary endpoint. The first patient achieved insulin independence 270 days into treatment, lasting through month 24 of the follow-up. The patient had type 1 diabetes (T1D) for “nearly 42 years,” according to Vertex's announcement, and was taking 34 units of insulin daily. Insulin independence came on day 180 for the second patient, persisting through 12 months of follow-up. The patient had T1D for 19 years and was taking 45.1 units of exogenous insulin daily. This patient had to restart insulin treatment at month 15, though at a much lower daily dose of four units. The third patient stopped needing insulin at 180 days of treatment, which happened after the data cut-off, according to Vertex. Aside from insulin independence, the new data from the Phase I/II study showed that VX-880 induced islet cell engraftment in all participants in parts A and B of the study at 90 days. In turn, these patients are now capable of endogenous glucose-responsive insulin production and demonstrated better glycemic control across various measures, including HbA1c and time-in-range. Before receiving VX-880, all enrolled participants had long-standing T1D and showed no signs of endogenous insulin secretion and required 34.0 units of insulin per day on average, according to Vertex's announcement on Tuesday. All patients also had histories of recurrent severe hypoglycemic events. An investigational allogeneic stem cell-based therapeutic, VX-880 works by delivering fully differentiated and insulin-producing islet cells, in turn restoring the body's glucose-responsive insulin production capabilities and boosting glucose control. VX-880 is designed to be delivered via an infusion through the hepatic portal vein. Patients need to be on an immunosuppressive regimen to receive the candidate. Vertex's T1D program also includes VX-264, an investigational therapy that encapsulates stem cell-derived islet cells in a protective device to be implanted into the patients' bodies, according to the company's website. Because the device is designed to shield the therapeutic cells from the body's response, VX-264 is being studied without the use of immunosuppressive therapies. https://www.biospace.com/article/vertex-touts-promising-data-for-stem-cell-based-type-1-diabetes-treatment/ XX I mentioned Dexcom's presentation at EASD in our long format interview earlier this week.. One of the company's studies, for example, recruited insulin users in the U.K. to test out the Dexcom ONE device, which offers a more simplified interface compared to the company's flagship G-series sensors. Though both Type 1 and Type 2 patients joined the study, Dexcom specifically singled out its results in the Type 2 population: The group saw their average HbA1c levels drop from a baseline of just over 10% to 8.5% after three months, then down to 8.3% after another three months, according to a company release. The data marked the first real-world study conducted on the Dexcom ONE CGM, Leach said. Another study presented at the EASD conference this week verified the use of the G7 sensor in pregnant women with Type 1, Type 2 or gestational diabetes—making Dexcom's G6 and G7 devices the only commercially available CGMs backed by clinical data for use during pregnancy, the company said. That group makes up about 10% of all pregnancies, he said, and “whether you're on insulin therapy or not, just the benefit of having a Supported by those findings, Dexcom said in the release that it now plans to make the G7 sensor available for use with Tandem's t:slim X2 insulin pump in the U.S. and “multiple markets across Europe and Asia-Pacific” before the end of 2023. https://www.fiercebiotech.com/medtech/easd-dexcom-cgms-notch-wins-among-type-2-and-pregnant-users-and-7-year-real-world-data XX Metformin may lengthen the time until insulin initiation, lower fasting glucose and improve neonatal outcomes for pregnant women with gestational diabetes, according to data from a randomized trial. In findings presented at the European Association for the Study of Diabetes annual meeting and simultaneously published in JAMA, researchers compared glycemic, maternal and neonatal outcomes for women with gestational diabetes randomly assigned up to 2,500 mg metformin daily with those receiving placebo. The metformin group had a lower mean fasting glucose at 32 and 38 weeks of gestation, and the offspring of women receiving metformin had a lower mean birth weight than the offspring of those receiving placebo. Metformin reduces the likelihood for large for gestational age among offspring of women with gestational diabetes. Infants from mothers in the metformin group had a lower mean birth weight than offspring of mothers from the placebo group (3,393 g vs. 3,506 g; P = .005). The percentage of infants born large for gestational age was lower in the metformin group vs. placebo (6.5% vs. 14.9%; P = .003). Mean crown-to-heel length was shorter in offspring of mothers from the metformin group compared with placebo (51 cm vs. 51.7 cm; P = .02). “Caution should continue with metformin and small for gestational age, especially in those where small for gestational age may be more likely, so those with hypertension or nephropathy,” Dunne said during the presentation. https://www.healio.com/news/endocrinology/20231004/metformin-provides-glycemic-neonatal-benefits-for-women-with-gestational-diabetes XX More voices are calling for more screening for type 1 diabetes. About 85% of people with type have no family history. Various research programs are going on worldwide to establish the best ways of implementing universal screening, including programs in Germany, the USA, Israel, the UK, and Australia. A new program (Edent1fi) has just been funded that will include multiple new European countries, including the UK, Germany, Poland, Portugal, Italy, and the Czech Republic. "These are all research programs. The next steps before universal screening for type 1 diabetes becomes general policy will require guidelines for monitoring and endorsement of screening and monitoring guidelines by applicable societies," explains Dr. Sims. This will also be helped by broader access to disease-modifying therapies to impact progression and the need to start insulin injections. Screening for adults, who can also develop T1D, is less well studied. Although optimal approaches have yet to be elucidated, this population will also likely benefit from identifying early-stage disease and the advantages of education, monitoring, and access to therapy. https://www.news-medical.net/news/20231003/Universal-screening-A-game-changer-in-early-detection-and-management-of-type-1-diabetes.aspx XX As I mentioned briefly in my last episode, one of the winners of this year's Nobel prize for medicine has lived with type 1 for almost 60 years. Dr. Drew Weissman and Katalin Karikó won the Nobel for their work on the COVID-19 vaccines received a Nobel Prize of Medicine. Karikó and Weissman met by chance in the 1990s while photocopying research papers, Karikó told The Associated Press. Weissman was diagnosed at age 5 and I'll link up a great interview that Mike Hoskins posted – he used to write for DiabetesMine. http://www.thediabeticscornerbooth.com/2021/02/we-can-thank-this-researcher-with-type.html?m=1&fbclid=IwAR254vGL8G0aU3uUnvfHbJa79WCiFgS8ihMgHMf0V2hK2QYJBLaa9zwMn7U XX Should women be screened for type 2 diabetes at a younger age than men? A recent study published in Diabetes Therapy explores this hypothesis – there's a lot here and I'll link it up, but they examine the theory that menstruation can throw off an A1C. Women with diabetes between 16-60 years of age have an increased mortality risk by about 27% as compared to diabetic men of the same age when both are compared to the general population. Women lose an average of 5.3 years from their lifespan with diabetes as compared to 4.5 years for men. The study comprised two cohorts. The first included over 146,000 individuals using a single HbA1c reading at or below 50 mmol/mol obtained between 2012 and 2019. The distribution was replicated using readings from a second cohort of about 940,000 people, whose samples were analyzed in six laboratories between 2019 and 2021. The mean HbA1c level in women at any given age corresponded to that observed in men up to ten years earlier. These findings were corroborated with data obtained from the second cohort. An undermeasurement of approximately 1.6 mmol/mol HbA1c in women may delay their diabetes diagnosis by up to ten years. Ten years in which they weren't being treated. https://www.news-medical.net/news/20231004/The-cut-off-for-HbA1c-based-diagnosis-of-diabetes-may-be-too-high-in-women.aspx XX Commercial – Edgepark XX XX Very recently, the Americans with Diabetes Association released updated CGM guidance for use in schools. The link to the new guidance is below. This came about after discussions with stakeholders, including myself and Attorney Roswig. Be clear, this was revised because of the discussions and “rallying” of families impacted, where in some cases schools were pointing to certain flaws in the language in the prior guidance. While this new guidance may address your CGM issue with your particular school, the new guidance, in our opinion, still needs work. Please know that this work will continue. If you have any more specific questions, please contact me and I will attempt to address the same. Thank you for your patience, thus far, and anticipated trust and patience going forward. https://diabetes.org/sites/default/files/2023-09/cgm-final-9-22-23.pdf?fbclid=IwAR1t4cpPUSmDoitWiH2hSgNnXWdeYQjPW4rlewjWkWHiOYWc65HX8ub74Yo XX have to show everyone and show myself that this doesn't change anything,” said Lauren Dahlin about her diagnosis with type 1 diabetes (T1D) at 26 years old in 2017. Today, she's a true athlete who has competed in nine Ironman races — consisting of a 2.4-mile swim, a 112-mile bike ride, and a 26.2-mile run. Completed within about 14 hours! This past summer, Dahlin competed in the annual Ironman in Lake Placid, NY. The event came with a lot of pressure because placing within the top 24 racers meant qualifying for the biggest Ironman event of all: the World Championship in Kona, HI. She did it. Dahlin placed 9th amongst about 600 other female competitors — becoming one of the first women with T1D to qualify for the Ironman in Kona, HI. Happening next weekend Oct 14th Here's a closer look at Dahlin's journey from diagnosis to rockstar competitive athlete. Diagnosed just days before a potential DKA coma “I couldn't even walk half a flight of stairs without getting extremely winded because I was so far gone,” explains Dahlin of her pre-diagnosis symptoms. “The clinic gave me an inhaler for asthma and sent me home!” Dahlin saw six different providers before someone finally gave her the appropriate diagnosis. They even performed a full-blood panel workup and didn't diagnose her T1D. Eventually, Dahlin went to the emergency room in Boston, where she lived, and the staff told her she was experiencing diabetic ketoacidosis (DKA). She then spent ten days in the intensive care unit learning about her new life living with T1D. “I was bummed that the doctors hadn't caught my diagnosis earlier because there were a lot of clinical trials happening in Boston that I could have been a part of.” Regardless, Dahlin didn't want to slow down — within one month of her diagnosis, she signed up for her first half-marathon. https://t1dexchange.org/ironman-world-championship-type-1-diabetes/ XX That's In the News for this week.. if you like it, please share it! Thanks for joining me! See you back here soon.
Did you know that antivirals can lower the risk of COVID-19 hospitalization or death in high-risk individuals? Credit available for this activity expires: 9/20/24 Earn Credit / Learning Objectives & Disclosures: https://www.medscape.org/viewarticle/996557?ecd=bdc_podcast_libsyn_mscpedu
Did you know that antivirals can significantly reduce the risk of hospitalization and death associated with COVID-19 in high-risk patients? Credit available for this activity expires: 8/23/2024 Earn Credit / Learning Objectives & Disclosures: https://www.medscape.org/viewarticle/995721?ecd=bdc_podcast_libsyn_mscpedu
Ever wonder how Antibiotics work? How do they differ from Antivirals? If they're so great, why don't we just always take or prescribe them so we don't get sick? Is Antibiotic resistance a real threat? Well, we hope you wonder about these things because that's what Jason spent all week researching to teach you in this one. Enjoy!” --- Support this podcast: https://podcasters.spotify.com/pod/show/guardianpodcast/support
A lot has been said about COVID antivirals, especially on how they might help bring down the number of deaths from the disease.But occasionally an interesting phenomenon occurs: a patient takes the antiviral drugs, feels better, only to come down with COVID again.So how do COVID antivirals work and why does the rebound sometimes happen?
A lot has been said about COVID antivirals, especially on how they might help bring down the number of deaths from the disease. But occasionally an interesting phenomenon occurs: a patient takes the antiviral drugs, feels better, only to come down with COVID again. So how do COVID antivirals work and why does the rebound sometimes happen?
A lot has been said about COVID antivirals, especially on how they might help bring down the number of deaths from the disease. But occasionally an interesting phenomenon occurs: a patient takes the antiviral drugs, feels better, only to come down with COVID again. So how do COVID antivirals work and why does the rebound sometimes happen?
In this episode, Renslow Sherer, MD, and Trinh P. Vu, PharmD, BCIDP, discuss strategies for managing ambulatory patients with acute or previous COVID-19 infection, including:Current COVID-19 landscapeRapid antigen tests and PCR testsRisk stratification of patients who have a positive SARS-CoV-2 testAntiviral treatment (nirmatrelvir + ritonavir, remdesivir, and molnupiravir)Long COVIDPresenters:Renslow Sherer, MDDirector, International HIV Training CenterProfessor of MedicineSection of Infectious Diseases and Global HealthDepartment of MedicineUniversity of ChicagoChicago, IllinoisTrinh P. Vu, PharmD, BCIDPClinical Pharmacy Specialist in Infectious DiseasesDepartment of Pharmaceutical ServicesEmory University Hospital MidtownAtlanta, GeorgiaTo download the slides: bit.ly/3oHKC09To view the full online program: bit.ly/4201xcO
In this episode, Tracey Piparo, PA-C, and Renslow Sherer, MD, discuss cases of nonhospitalized patients with COVID-19, including:Young, healthy patient with no risk factorsYoung, healthy patient with risk factorsOlder patient with immunocompromiseOlder patient with renal dysfunctionPatient experiencing hypoxia Presenters: Tracey Piparo, PA-C Department of Palliative Medicine RJWBarnabas New Brunswick, New Jersey Renslow Sherer, MD Director, International HIV Training Center Professor of Medicine Section of Infectious Diseases and Global Health Department of Medicine University of Chicago Chicago, Illinois To download the slides: bit.ly/44cgH0qTo view the full online program: https://bit.ly/4201xcO
More than 2 million individuals in the US are chronically infected with hepatitis C, and nearly 15 000 die every year. Antivirals are available but are not reaching the majority of infected individuals. In this Q&A, JAMA Editor in Chief Kirsten Bibbins-Domingo, PhD, MD, MAS, and Francis S. Collins, MD, PhD, discuss a plan to eliminate hepatitis C included in the Biden-Harris 2024 budget proposal. Related Content: A National Hepatitis C Elimination Program in the United States Eliminating Hepatitis C in the United States Former NIH Director Francis S. Collins on the New White House Plan to Eliminate Hepatitis C Association of Direct-Acting Antiviral Therapy With Liver and Nonliver Complications and Long-term Mortality in Patients With Chronic Hepatitis C After 12 Years, NIH Director Francis S. Collins, MD, PhD, Seeks His Next Chapter After 12 Years, NIH Director Francis S. Collins Seeks His Next Chapter
More than 2 million individuals in the US are chronically infected with hepatitis C, and nearly 15 000 die every year. Antivirals are available but are not reaching the majority of infected individuals. In this Q&A, JAMA Editor in Chief Kirsten Bibbins-Domingo, PhD, MD, MAS, and Francis S. Collins, MD, PhD, discuss a plan to eliminate hepatitis C included in the Biden-Harris 2024 budget proposal. Related Content: A National Hepatitis C Elimination Program in the United States Eliminating Hepatitis C in the United States Former NIH Director Francis S. Collins on the New White House Plan to Eliminate Hepatitis C Association of Direct-Acting Antiviral Therapy With Liver and Nonliver Complications and Long-term Mortality in Patients With Chronic Hepatitis C After 12 Years, NIH Director Francis S. Collins, MD, PhD, Seeks His Next Chapter After 12 Years, NIH Director Francis S. Collins Seeks His Next Chapter
Antivirals are an important measure to prevent severe disease in vulnerable people with COVID-19. But there have been concerns antivirals could lead to rebound infections — the resurgence of viral load following the completion of the medication. So what do the latest studies say? Also, we speak to an expert informing the parliamentary inquiry into long COVID about how to best care for patients. Guest: Professor Tania Sorrell University of Sydney References: SARS-CoV-2 rebound with and without antivirals Viral burden rebound in hospitalised patients with COVID-19 receiving oral antivirals in Hong Kong: a population-wide retrospective cohort study Submission—Inquiry into long COVID and repeated COVID infections
Antivirals are an important measure to prevent severe disease in vulnerable people with COVID-19. But there have been concerns antivirals could lead to rebound infections — the resurgence of viral load following the completion of the medication. So what do the latest studies say?Also, we speak to an expert informing the parliamentary inquiry into long COVID about how to best care for patients. Guest: Professor Tania SorrellUniversity of SydneyReferences: SARS-CoV-2 rebound with and without antiviralsViral burden rebound in hospitalised patients with COVID-19 receiving oral antivirals in Hong Kong: a population-wide retrospective cohort studySubmission—Inquiry into long COVID and repeated COVID infections
Antivirals are an important measure to prevent severe disease in vulnerable people with COVID-19. But there have been concerns antivirals could lead to rebound infections — the resurgence of viral load following the completion of the medication. So what do the latest studies say? Also, we speak to an expert informing the parliamentary inquiry into long COVID about how to best care for patients. Guest: Professor Tania Sorrell University of Sydney References: SARS-CoV-2 rebound with and without antivirals Viral burden rebound in hospitalised patients with COVID-19 receiving oral antivirals in Hong Kong: a population-wide retrospective cohort study Submission—Inquiry into long COVID and repeated COVID infections
Hour 1 * Guest: Chris Carlson – Without God, we can never win, With God, we can never lose, The Battle for Freedom is the Lord's, but we need to be engaged in the fight! * Beware of Compromise Behind the Scenes! * How will speaker of the House McCarthy betray us now? * McCarthy's Track Record – Daniel Horowitz, TheBlaze.com. * ‘Close, but no cigar'! Hour 2 * Sam and Chris Debate The Pros and Cons of Term Limits. * Democrats Decried Dark Money. Then They Won With It in 2020. * “you cannot find that for which you do not look” – Dr. Ryan Cole. * Vitamin D Epidemic! * Another YouTube Video Taken Down. * Ivermectin and Hydroxychloroquine are Antivirals. * Molluscum Contagiosum in the Elderly and Children. * We had federal agents…saying, “Don't do autopsies. We're not going to look at that. We're not going to fund that.” * When you hear, “Don't study that. Don't do autopsies,” why wouldn't we. “Don't look at that database. Why? Why wouldn't we, of course we should. This is about, obviously, it's about a virus. It's about humanity. It's about the human condition, but it is bad science not to look, you cannot find that for which you do not look. * Get the government out of the people's medical care. The government, policymakers don't need to be dictating what treatment you do or don't get. Let doctors be doctors and prescribe medicines that are safe and effective. Don't punish them for being good doctors and protect the children. Don't ever experiment on the children. --- Support this podcast: https://anchor.fm/loving-liberty/support
Welcome to Episode 21 of “The 2 View,” the podcast for EM and urgent care nurse practitioners and physician assistants! Links To Our Live Courses Advanced EM Boot Camp Course: https://courses.ccme.org/course/advancedbootcamp Original EM Boot Camp Course: https://courses.ccme.org/course/embootcamp Emergency Medicine & Acute Care Series Course: https://courses.ccme.org/course/ema Recurring Sources Center for Medical Education. Ccme.org. http://ccme.org The Proceduralist. Theproceduralist.org. http://www.theproceduralist.org The Procedural Pause. Emergency Medicine News. Lww.com. https://journals.lww.com/em-news/blog/theproceduralpause/pages/default.aspx The Skeptics Guide to Emergency Medicine. Thesgem.com. http://www.thesgem.com Trivia Question: Send answers to 2viewcast@gmail.com Be sure to keep tuning in for more great prizes and fun trivia questions! Once you hear the question, please email us your guesses at 2viewcast@gmail.com and tell us who you want to give a shout-out to. Be sure to listen in and see what we have to share!
In this new episode of our coronavirus podcast, we discuss a study that looked at the effects of Paxlovid on long COVID symptoms, and we also talk new bivalent boosters and immunity.
This Week In Wellness a review published in the Biomolecules journal has suggested that melatonin may be more effective in reducing long covid symptoms and COVID-19 inflammatory markers than commonly used antivirals. The authors have suggested that the reason it has not been promoted more as a solution is due to its easy availability and the fact that it cannot be patented by pharmaceutical manufacturers. https://www.news-medical.net/news/20221109/Melatonin-could-be-a-potential-therapy-for-long-COVID-symptoms.aspx. https://www.mdpi.com/2218-273X/12/11/1646.
What's the difference between COVID reinfection, rebounding, and a new infection? Are people contagious and can they have recurring symptoms with a COVID rebound? Can antivirals like paxlovid cause COVID rebounds? Can paxlovid prevent long COVID? Amesh Adalja returns to the podcast to talk with Josh Sharfstein and answer your questions sent to publichealthquestion@jhu.edu.
This week we will discuss Monkeypox with Dr. Tiffany Najberg. Dr. Tiffany Alexis Najberg Pronouns: She/her Physician licensed in the state of Louisiana Dr. Tiffany is a Board Certified Emergency Physician who has served in busy emergency departments and provided prehospital care as well as remote care since 2007. A transwoman currently transitioning herself, she is the first open trans woman Emergency Physician in Louisiana. She is a business owner who co owns her clinic, UrgentEMS, in Shreveport Louisiana. She practices urgent care, some primary care, and gender affirming care there and via telehealth throughout the state. Her experience in remote medical direction led her to begin practicing transgender medicine via telemedicine, as making it accessible to all, even in isolated locations, is something she cares deeply about. She received her medical degree at the University of North Texas in Fort Worth, completed her emergency medicine residency at LSU New Orleans (Charity Hospital), and her EMS fellowship with New Orleans EMS. She has been a teaching staff at Ochsner in New Orleans and St. Francis in Monroe, and has a passion for medical education. She still actively instructs medical students at her clinic. Her non medical interests include amateur storm chasing, writing, all things social, and she is a fierce advocate for public health, trans rights, women's rights, and lgbtq+ issues through her sizable online platforms. Dr. Tiffany goes more in depth about this new form of pox quickly spreading around the world. Symptoms of monkeypox can include Fever Headache Muscle aches and backache Swollen lymph nodes Chills Exhaustion Respiratory symptoms (e.g. sore throat, nasal congestion, or cough) A rash that may be located on or near the genitals (penis, testicles, labia, and vagina) or anus (butthole) but could also be on other areas like the hands, feet, chest, face, or mouth. The rash will go through several stages, including scabs, before healing. The rash can look like pimples or blisters and may be painful or itchy. You may experience all or only a few symptoms Sometimes, people get a rash first, followed by other symptoms. Others only experience a rash. Most people with monkeypox will get a rash. Some people have developed a rash before (or without) other symptoms. Monkeypox symptoms usually start within 3 weeks of exposure to the virus. If someone has flu-like symptoms, they will usually develop a rash 1-4 days later. Monkeypox can be spread from the time symptoms start until the rash has healed, all scabs have fallen off, and a fresh layer of skin has formed. The illness typically lasts 2-4 weeks. If You Have a New or Unexplained Rash or Other Symptoms... Avoid close contact, including sex or being intimate with anyone, until you have been checked out by a healthcare provider. If you don't have a provider or health insurance, visit a public health clinic near you. When you see a healthcare provider, wear a mask, and remind them that this virus is circulating in the area. Monkeypox spreads in a few ways. Monkeypox can spread to anyone through close, personal, often skin-to-skin contact, including: Direct contact with monkeypox rash, scabs, or body fluids from a person with monkeypox. Touching objects, fabrics (clothing, bedding, or towels), and surfaces that have been used by someone with monkeypox. Contact with respiratory secretions. This direct contact can happen during intimate contact, including: Oral, anal, and vaginal sex or touching the genitals (penis, testicles, labia, and vagina) or anus (butthole) of a person with monkeypox. Hugging, massage, and kissing. Prolonged face-to-face contact. Touching fabrics and objects during sex that were used by a person with monkeypox and that have not been disinfected, such as bedding, towels, fetish gear, and sex toys. A pregnant person can spread the virus to their fetus through the placenta. It's also possible for people to get monkeypox from infected animals, either by being scratched or bitten by the animal or by preparing or eating meat or using products from an infected animal. A person with monkeypox can spread it to others from the time symptoms start until the rash has fully healed and a fresh layer of skin has formed. The illness typically lasts 2-4 weeks. Scientists are still researching: If the virus can be spread when someone has no symptoms How often monkeypox is spread through respiratory secretions, or when a person with monkeypox symptoms might be more likely to spread the virus through respiratory secretions. Whether monkeypox can be spread through semen, vaginal fluids, urine, or feces. Protect Yourself and Others Following the recommended prevention steps and getting vaccinated if you were exposed to monkeypox or are at higher risk of being exposed to monkeypox can help protect you and your community. Take the following steps to prevent getting monkeypox: Avoid close, skin-to-skin contact with people who have a rash that looks like monkeypox. Do not touch the rash or scabs of a person with monkeypox. Do not kiss, hug, cuddle or have sex with someone with monkeypox. Avoid contact with objects and materials that a person with monkeypox has used. Do not share eating utensils or cups with a person with monkeypox. Do not handle or touch the bedding, towels, or clothing of a person with monkeypox. Wash your hands often with soap and water or use an alcohol-based hand sanitizer, especially before eating or touching your face and after you use the bathroom. In Central and West Africa, avoid contact with animals that can spread monkeypox virus, usually rodents and primates. Also, avoid sick or dead animals, as well as bedding or other materials they have touched. CDC recommends vaccination for people who have been exposed to monkeypox and people who may be more likely to get monkeypox. People more likely to get monkeypox include: People who have been identified by public health officials as a contact of someone with monkeypox People who are aware that one of their sexual partners in the past 2 weeks has been diagnosed with monkeypox People who had multiple sexual partners in the past 2 weeks in an area with known monkeypox People whose jobs may expose them to orthopoxviruses, such as: Laboratory workers who perform testing for orthopoxviruses Laboratory workers who handle cultures or animals with orthopoxviruses Some designated healthcare or public health workers Treatment There are no treatments specifically for monkeypox virus infections. However, monkeypox and smallpox viruses are genetically similar, which means that antiviral drugs and vaccines developed to protect against smallpox may be used to prevent and treat monkeypox virus infections. Antivirals, such as tecovirimat (TPOXX), may be recommended for people who are more likely to get severely ill, like patients with weakened immune systems. If you have symptoms of monkeypox, you should talk to your healthcare provider, even if you don't think you had contact with someone who has monkeypox. (Credits: CDC)
This week we will discuss the basics about Monkeypox. We will have Dr. Tiffany Najberg on the show in two weeks to go more in depth about this new form of pox quickly spreading around the world. Symptoms of monkeypox can include: Fever Headache Muscle aches and backache Swollen lymph nodes Chills Exhaustion Respiratory symptoms (e.g. sore throat, nasal congestion, or cough) A rash that may be located on or near the genitals (penis, testicles, labia, and vagina) or anus (butthole) but could also be on other areas like the hands, feet, chest, face, or mouth. The rash will go through several stages, including scabs, before healing. The rash can look like pimples or blisters and may be painful or itchy. You may experience all or only a few symptoms Sometimes, people get a rash first, followed by other symptoms. Others only experience a rash. Most people with monkeypox will get a rash. Some people have developed a rash before (or without) other symptoms. Monkeypox symptoms usually start within 3 weeks of exposure to the virus. If someone has flu-like symptoms, they will usually develop a rash 1-4 days later. Monkeypox can be spread from the time symptoms start until the rash has healed, all scabs have fallen off, and a fresh layer of skin has formed. The illness typically lasts 2-4 weeks. If You Have a New or Unexplained Rash or Other Symptoms... Avoid close contact, including sex or being intimate with anyone, until you have been checked out by a healthcare provider. If you don't have a provider or health insurance, visit a public health clinic near you. When you see a healthcare provider, wear a mask, and remind them that this virus is circulating in the area. Monkeypox spreads in a few ways. Monkeypox can spread to anyone through close, personal, often skin-to-skin contact, including: Direct contact with monkeypox rash, scabs, or body fluids from a person with monkeypox. Touching objects, fabrics (clothing, bedding, or towels), and surfaces that have been used by someone with monkeypox. Contact with respiratory secretions. This direct contact can happen during intimate contact, including: Oral, anal, and vaginal sex or touching the genitals (penis, testicles, labia, and vagina) or anus (butthole) of a person with monkeypox. Hugging, massage, and kissing. Prolonged face-to-face contact. Touching fabrics and objects during sex that were used by a person with monkeypox and that have not been disinfected, such as bedding, towels, fetish gear, and sex toys. A pregnant person can spread the virus to their fetus through the placenta. It's also possible for people to get monkeypox from infected animals, either by being scratched or bitten by the animal or by preparing or eating meat or using products from an infected animal. A person with monkeypox can spread it to others from the time symptoms start until the rash has fully healed and a fresh layer of skin has formed. The illness typically lasts 2-4 weeks. Scientists are still researching: If the virus can be spread when someone has no symptoms How often monkeypox is spread through respiratory secretions, or when a person with monkeypox symptoms might be more likely to spread the virus through respiratory secretions. Whether monkeypox can be spread through semen, vaginal fluids, urine, or feces. Protect Yourself and Others Following the recommended prevention steps and getting vaccinated if you were exposed to monkeypox or are at higher risk of being exposed to monkeypox can help protect you and your community. Take the following steps to prevent getting monkeypox: Avoid close, skin-to-skin contact with people who have a rash that looks like monkeypox. Do not touch the rash or scabs of a person with monkeypox. Do not kiss, hug, cuddle or have sex with someone with monkeypox. Avoid contact with objects and materials that a person with monkeypox has used. Do not share eating utensils or cups with a person with monkeypox. Do not handle or touch the bedding, towels, or clothing of a person with monkeypox. Wash your hands often with soap and water or use an alcohol-based hand sanitizer, especially before eating or touching your face and after you use the bathroom. In Central and West Africa, avoid contact with animals that can spread monkeypox virus, usually rodents and primates. Also, avoid sick or dead animals, as well as bedding or other materials they have touched. CDC recommends vaccination for people who have been exposed to monkeypox and people who may be more likely to get monkeypox. People more likely to get monkeypox include: People who have been identified by public health officials as a contact of someone with monkeypox People who are aware that one of their sexual partners in the past 2 weeks has been diagnosed with monkeypox People who had multiple sexual partners in the past 2 weeks in an area with known monkeypox People whose jobs may expose them to orthopoxviruses, such as: Laboratory workers who perform testing for orthopoxviruses Laboratory workers who handle cultures or animals with orthopoxviruses Some designated healthcare or public health workers Treatment There are no treatments specifically for monkeypox virus infections. However, monkeypox and smallpox viruses are genetically similar, which means that antiviral drugs and vaccines developed to protect against smallpox may be used to prevent and treat monkeypox virus infections. Antivirals, such as tecovirimat (TPOXX), may be recommended for people who are more likely to get severely ill, like patients with weakened immune systems. If you have symptoms of monkeypox, you should talk to your healthcare provider, even if you don't think you had contact with someone who has monkeypox. (Credits: CDC)
The federal “test-to-treat” program was designed to reduce hospitalizations and deaths by getting antivirals to people who test positive for COVID-19 as quickly as possible. Hannah Recht, a reporter at Kaiser Health News who has written about the topic, talks to Stephanie Desmon about how confusing websites, lack of up-to-date information and costs have kept many of the neediest from receiving prompt care.
In-patient treatment for severe COVID has come a long way since 2020 thanks, in part, to the rare opportunity of real-time data collection from so many people sick with the same disease at the same time. Dr. Brian Garibaldi, director of the Johns Hopkins Biocontainment Unit, returns to the podcast to talk with Stephanie Desmon about treating severely ill COVID patients, advances in therapeutics like antivirals and anti-inflammatory treatments, and why vaccines remain “the most astounding achievements.”
Andy brings you information directly from the source to let you know what to expect when the antivirals arrive: who will get them, how to get them, when to get yours, and the biggest question — will they change everything? In an exclusive interview with In the Bubble, Dr. David Kessler, Chief Science Officer of the White House COVID-19 Response Team, tells Andy how he is personally navigating Omicron and what the Biden Administration is doing to ensure that we have the capacity to respond quickly to the next pandemic. Keep up with Andy on Twitter @ASlavitt and Instagram @andyslavitt. Follow David @DavidAKesslerMD on Twitter. Joining Lemonada Premium is a great way to support our show and get bonus content. Subscribe today at bit.ly/lemonadapremium. Support the show by checking out our sponsors! Click this link for a list of current sponsors and discount codes for this show and all Lemonada shows: https://lemonadamedia.com/sponsors/ Throughout the pandemic, CVS Health has been there, bringing quality, affordable health care closer to home—so it's never out of reach for anyone. Because at CVS Health, healthier happens together. Learn more at cvshealth.com. Check out these resources from today's episode: Learn more about the NIH's COVID-19 treatment guidelines: https://www.covid19treatmentguidelines.nih.gov/ Check out the New England Journal of Medicine article on Remdesivir that David mentions in today's episode: https://www.nejm.org/doi/full/10.1056/NEJMoa2116846 Find a COVID-19 vaccine site near you: https://www.vaccines.gov/ Order Andy's book, Preventable: The Inside Story of How Leadership Failures, Politics, and Selfishness Doomed the U.S. Coronavirus Response: https://us.macmillan.com/books/9781250770165 Stay up to date with us on Twitter, Facebook, and Instagram at @LemonadaMedia. For additional resources, information, and a transcript of the episode, visit lemonadamedia.com/show/inthebubble. See omnystudio.com/listener for privacy information.
© 2020-2025 Ivy Podcast Discovery LLC
